Hans-Juergen Woerle is a highly accomplished physician-scientist, trained in cardio-renal metabolism, and a board-certified internist, endocrinologist and diabetologist with senior R&D executive expertise across the entire drug development continuum. He previously served as Global Vice President Medicine, Cardio-Renal-Metabolism, at Boehringer Ingelheim, where he headed the company’s entire cardio-renal-metabolic franchise. There, he designed EMPA-REG OUTCOME, the first trial to demonstrate a cardiovascular-mortality reduction in type 2 diabetes, personally defended it before the FDA Advisory Committee to secure the first-ever FDA cardiovascular-mortality claim for a diabetes medicine, and shaped the outcome programme that followed in heart failure and chronic kidney disease. More recently, he was Chief Scientific and Medical Officer at Nestlé Health Science, where he was instrumental in transforming the organization into a science-driven healthcare business, played a critical role in the development and successful commercial transaction of Vowst®, the first FDA-approved oral microbiome therapy, and contributed to several landmark deals and product launches. He brings substantial M&A and investor-side experience across multiple acquisitions, in-licensing transactions and R&D collaborations. He advises biotech boards, CEOs and investors at asset-defining inflection points and serves as Non-Executive Director and Chair of the R&D Committee at MRM Health. He holds an MD from the University of Munich and is Visiting Professor at the Université de Lausanne and Adjunct Professor at the University of Ulm.